362 related articles for article (PubMed ID: 3276721)
1. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
[TBL] [Abstract][Full Text] [Related]
2. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
5. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B.
Goldberg RB; Rabin D; Alexander AN; Doelle GC; Getz GS
J Clin Endocrinol Metab; 1985 Jan; 60(1):203-7. PubMed ID: 3917267
[TBL] [Abstract][Full Text] [Related]
6. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
7. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
8. Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions.
Leblanc M; Bélanger MC; Julien P; Tchernof A; Labrie C; Bélanger A; Labrie F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1849-57. PubMed ID: 15070955
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of flutamide action on prostatic and testicular functions in the rat.
Marchetti B; Labrie F
J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
[TBL] [Abstract][Full Text] [Related]
11. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
St-Arnaud R; Lachance R; Kelly SJ; Belanger A; Dupont A; Labrie F
Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
[TBL] [Abstract][Full Text] [Related]
12. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
13. Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma.
Wallentin L; Varenhorst E
Horm Metab Res; 1981 May; 13(5):293-7. PubMed ID: 7262828
[TBL] [Abstract][Full Text] [Related]
14. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
Walsh BW; Schiff I; Rosner B; Greenberg L; Ravnikar V; Sacks FM
N Engl J Med; 1991 Oct; 325(17):1196-204. PubMed ID: 1922206
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.
Moorjani S; Dupont A; Labrie F; De Lignieres B; Cusan L; Dupont P; Mailloux J; Lupien PJ
J Clin Endocrinol Metab; 1991 Aug; 73(2):373-9. PubMed ID: 1649840
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
17. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
Labrie F; Dupont A; Belanger A; Lachance R
J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
19. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Lacoste D; Dubé D; Bélanger A; Labrie F
Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
[TBL] [Abstract][Full Text] [Related]
20. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females.
Schaefer EJ; Foster DM; Zech LA; Lindgren FT; Brewer HB; Levy RI
J Clin Endocrinol Metab; 1983 Aug; 57(2):262-7. PubMed ID: 6408108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
